cidents, one third of which are fatal (Taylor etal., 1996). Hypertension also is thought to bethe most readily preventable and controllablefactor in congestive heart failure, a disease in-volved in more than 400,000 deaths and2,000,000 coronary events each year in theUnited States (Kannel et al., 1994).Given the magnitude of the causal roleplayed by hypertension in these diseaseprocesses, it is not surprising that many treat-ment alternatives have received considerableresearch attention (Kaplan, 1998a) (Table 1).Surprisingly, the vast majority of individuals(68%) who die as a result of the pathologicchanges associated with elevated blood pres-sure (BP) do so with systolic blood pressure of120–140 mm Hg and diastolic pressure below90 mm Hg. These ranges are below the thresh-old generally established for medical treatment(Joint National Committee on Detection, Eval-uation, and Treatment of High Blood Pressure,1997).According to the sixth report of the Joint Na-tional Committee on Detection, Evaluation andTreatment of High Blood Pressure (Joint Na-tional Committee on Detection, Evaluation,and Treatment of High Blood Pressure, 1997),hypertension is diagnosed when the systolic BPexceeds 140 mm Hg and/or the diastolic BP ex-ceeds 90 mm Hg. Alternatively, hypertensionis sometimes defined as the level of blood pres-sure elevation at which drug treatment is jus-tifiable (Kaplan, 1998b). Under this seconddefinition, a patient is diagnosed with hyper-tension when the effects of treatment are likelyto be less destructive than the elevated BP.With currently available drug treatments, thissituation is considered to be present when theaverage of multiple reliable readings amongpatients without concomitant risk factors ortarget organ damage exceeds 160 mm Hg sys-tolic BP and/or 95–100 mm Hg diastolic BP(Hoes, 1995; Joint National Committee on De-tection, Evaluation, and Treatment of HighBlood Pressure, 1997; Sever et al., 1993).Both of these criteria, however, leave mil-lions of people either medically unattended(i.e., below 160/95 mm Hg) and/or unin-formed (i.e., below 140/90 but still at elevatedrisk) of the seriousness of their condition. Drugtreatment below 160/95 mm Hg is usually notadvocated, and is rarely indicated below140/90 mm Hg (Kaplan, 1998c). Yet, a patientwith a BP of 136/88 mm Hg, for example, is atapproximately five times greater risk of strokethan a patient with a BP of 110/70 mm Hg(Stamler et al., 1993).A meta-analysis of nine prospective studiesalso found no evidence of a threshold level atwhich lower levels of BP were not associatedwith lower risks of stroke and congestive heartdisease (CHD) (MacMahon et al., 1990). A pos-itive linear association between BP and mor-tality was demonstrated, with an approximate
GOLDHAMER ET AL.644
T
ABLE
1.R
ESULTS OF
P
REVIOUS
S
TUDIES
R
EPORTING
B
LOOD
P
RESSURE
R
EDUCTIONS
A
SSOCIATED WITH
V
ARIOUS
I
NTERVENTIONS
S
TRATEGIES
SystolicDiastolic(mm Hg)(mm Hg)Source
Body weight loss
a
1.6
1.3Staessen et al. (1989
a
)
e
Sodium restriction
b
16.0
9.0MacGregor et al. (1989
a
)Vegetarian/high-fiber diet
2.8
1.1Appel et al. (1997
a
)Alcohol intake
c
4.8
3.3Puddey et al. (1992
a
)Exercise
d
0
6.50
6.5Arroll and Beaglehole (1992
a
)
e
Combination of low-fat, low-
17.0
13.0McDougall et al. (1995
a
)salt, vegan diet, and exerciseEffects of standard
12.0
6.0Kaplan (1998
a
)antihypertensivedrug treatment
a
Blood pressure reduction per kilogram of body weight loss.
b
Sodium intake reduced from 200 mmol/d to 50 mmol/d.
c
Reduction of alcohol intake from 440 mL to 66 mL/wk.
d
Average of 3 weekly events of aerobic activity.
e
Meta-analysis of studies.
Add a Comment